embecta to Participate in Investor Conferences
Get Alerts EMBC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.2%
Revenue Growth %: -14.0%
Join SI Premium – FREE
PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events:
2023 Mizuho Medical Device and Healthcare Services Summit
- Management will host one-on-one investor meetings on Wednesday, December 6, 2023, at Sofitel Hotel, New York.
2023 MedTech Madness Annual West Coast Bus Tour
- Management will host a fireside session on Monday, December 11, 2023, at 9:30 a.m. PT / 12:30 p.m. ET at the Montage at Laguna Beach, California.
About embecta
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ops+AI and Arrowhead Strategy Group Announce Strategic Partnership to Help Founders Build Smarter, Stronger, More Scalable Companies
- CoreAge Rx Achieves High Patient Satisfaction Ratings and Expands Member Support with New Wellness Community
- Julian Barnes Named Laureate of the 2026 Fitzgerald Prize
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, MizuhoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share